Danish Biotech Weekly – Week 23

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.

In the past week, ViroGates announced a deal with Sobi, Evaxion announced positive phase I results using its AI technology, and one management team sold more than 75 MDKK worth of shares.

10 of the 20 listed, Danish biotech companies have published news the past week. 8 of the 20 companies had a positive development in their share price for the week and 7 companies have had a positive share price performance year to date. Curasight continue to be the best performing stock this year.

Company news the past week

Ascendis Pharma

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates (Link)

Wedbush raises price target to $187.

Biosergen

Biosergen publishes interim report for first quarter 2023 (Link)

Cessatech

Cessatech provides positive news regarding shelf life of CT001 (Link)

CS Medica

No news the past week

Curasight

No news the past week

Evaxion Biotech

Evaxion Announces Business Update and First Quarter 2023 Financial Results (Link)

Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial (Link)

Expres2ion

No news the past week

Fluoguide

FluoGuide A/S publishes interim report for the period January – March 2023 (Link)

Genmab

Genmab’s CEO and CFO sold shares for a total of 75 MDKK.

Gubra

No news the past week

Initiator Pharma

Initiator Pharma’s IP2015 obtains the International Nonproprietary Name pudafensine (Link)

IO Biotech

IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead (Link)

Pila Pharma

No news the past week

Saniona

No news the past week

Scandion Oncology

No news the past week

SynAct Pharma

SynAct Pharma to present at the 2023 BIO International Convention (Link)

ViroGates

ViroGates announces an agreement with Sobi for the development of suPARnostic® for commercial use in the US in combination with Sobi’s Kineret® treatment for COVID-19-related pneumonia (Link)

Zealand Pharma

No news the past week

Y-mAbs Therapeutics

No news the past week

2cureX

No news the past week

SELECTED CASES

SHARE PRICE DEVELOPMENTS

The majority of the Danish Biotech stocks delivered a negative share price performance last week. The average return was -0.6%. Saniona rose 19% without any company news. ViroGates also performed well towards the end of the week following the deal with Sobi. On the other hand, 2Curex AB and Y-mAbs Therapeutics Inc. fell the most by 6-10%. Year to date a few companies have delivered excellent returns. Curasight A/S, Fluoguide A/S and Saniona AB have risen by 125-141% after among other things partnerships and positive recommendations paving the way for approvals.

Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment

Overview of share price developments the past week, year-to-date and last twelve months

Disclaimer 

Udvalgte investeringscases

Ønsker du at modtage et af vores nyhedsbreve? Udfyld venligst formularen nedenunder.

  • Investeringscases – Nyhedsbreve med top aktuelle investeringscases fra de nordiske vækstbørser og life science sektoren, og ugentlige markedsopdateringer..
  • Børsnoteringer – Opdateringer på nye og igangværende børsnoteringer i Skandinavien samt resultaterne af dem. (Nyhedsbrev fra Nyemission.dk)   
  • Nyheder – Nyheder fra og om Kapital Partner, herunder indsigt om kapitalmarkederne og børsnoteringer samt invitation til investormøder og- arrangementer.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*Hvis du ønsker information om vores kommende investeringsforening med fokus på de nordiske vækstbørser, herunder mulighed for at investere, så tilmeld dig nyhedsbrevet Nyheder.




Investornetværk:

Ønsker du at være en del af Kapital Partners investornetværk, hvor du får adgang til investeringer i selskaber og emissioner, samt indbydelse til investorrettede arrangementer
udfyld venligst formularen her.

Udvalgte cases

Del indlægget på sociale media eller på email. 

LinkedIn
Facebook
Twitter
Email